Now Trending

5 most popular innovation stories in Houston this week

One of this week's top stories is about a Houston company providing pain-relieving technology on the go. The Squid Team/Twitter

Editor's note: InnovationMap is starting strong — right out of the gate of 2019. From a restaurant-focused app to B2B companies making a splash in their industry's, the first trending stories post of the year has some great reads.

3 Houston innovators to know this week

These three entrepreneurs have a lot up their sleeves for 2019. Courtesy images

InnovationMap has three inspiring entrepreneurs to lead you into 2019. All three are behind Houston startups that are planning for big growth in the upcoming year. So, read their stories and get familiar with their names and faces — they aren't going anywhere. Read the full story here.

Restaurant-driven app focuses on Houston's food scene

Crityk's main goal is to be a marketing asset to restaurants. Getty Images

One night, Sumit Sikka was on a quest to find the best Moscow Mule in Santa Monica. He couldn't find anything helpful online, and when he finally did get a good recommendation, he was already done for the night.

It was through this experience that Sikka knew he wanted to make a restaurant finder app, but he wanted to do something different from Yelp or Google Reviews. On those platforms, a restaurant can get crushed by a bad review that provides false information. So, when he started getting the ball rolling on Crityk, he realized he needed to give the restaurants a voice. Read the full story here.

Houston company creates portable device that eases pain without the use of drugs

For years, Squid Compression has helped ease the pain of patients in doctor's offices. Now, anyone can get the treatment on the go. Photo via squidgo.com

Many of the estimated 50 million Americans who suffer from chronic pain turn to drugs — including heavily abused opioids — to relieve their symptoms. Houston-based startup Portable Therapeutix LLC's drug-free solution to pain management seeks to put a dent in the market for prescription painkillers.

In 2018, Houston-based Portable Therapeutix introduced Squid Go, a portable device that's designed to ease the pain and swelling of sore joints and muscles. It's a follow-up to the company's Squid Compression, a pain management device launched in 2013 for patients at rehabilitation centers, hospitals, doctor's offices, and the like. Read the full story here.

Houston software startup pivots to provide digital networking solutions

What started as a way to protect your company from a sketchy business partner has turned into a digital networking tool. Getty Images

Several years ago, David Grimes had a business partner who played dirty. It wasn't until the trial that followed the business wrongdoing that Grimes discovered the man had a history of cheating companies out of money. Grimes envisioned a software service that used public information to research potential investors or associates before signing on the dotted line of a partnership.

"I wanted to find a tool that would alleviate that pain and that risk of doing business," Grimes says. "I couldn't find that tool." Read the full story here.

Oil and gas startup exec positions Houston company for more growth in 2019

Christopher Robart leads Ambyint — a technology company creating the Nest thermostat for oil rigs — with his twin brother, Alex. Courtesy of Ambyint

Most of Christopher Robart's 10-year career in oil and gas has been deliberate and calculated — researching the right startup to be involved in or finding the right buyer for a company he invested in. However, his actual start in the industry wasn't so intentional.

"I sort of fell into oil and gas after I got of college back in 2003," says Robart, who is the president of Ambyint USA. "Before that, I was involved in a few startup things — some digital and some not. I was always sort of an entrepreneur." Read the full story here.


Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted